Search
Findings about proteins called molecular chaperones are shedding new light on possible approaches to cancer treatment.
Eight leading cancer centers are coming together to share genomic sequencing data, in the hope of making faster progress in curing cancer.
Dr. Emmanouil Pappou urges the importance of routine cancer screenings, even during COVID-19, on the TODAY Show.
Learn more about how MSK is developing new treatments for osteosarcoma and other bone cancers.
Researchers from Memorial Sloan Kettering Cancer Center (MSK), in collaboration with an international research team, have discovered that DNA circles can contribute to the development of childhood cancers. The team, led by MSK computational biologist Richard Koche and Anton Henssen of Charité University Hospital Berlin, made this discovery by studying extrachromosomal DNA in neuroblastoma cells. Neuroblastoma develops in immature nerve cells and is the most common form of cancer in infants.
An antibody test developed at MSK could shed light on the immune response to the COVID-19 virus.
Blood pressure should be monitored closely and on an ongoing basis for several months after initiating ibrutinib treatment in patients with chronic lymphocytic leukemia (CLL), according to our retrospective study.
根据我们的回顾性研究,在慢性淋巴细胞白血病 (CLL) 患者开始接受伊鲁替尼治疗后,应密切监测其血压,并持续数月。
Memorial Sloan Kettering Cancer Center (MSK) researchers presented the results of a randomized phase III trial at today’s press program for the European Society for Medical Oncology’s 2018 Congress in Munich, Germany. The results demonstrated that a combination of the immune checkpoint blocker avelumab (Bavencio®) and the tyrosine kinase inhibitor (TKI) axitinib (Inlyta®) can significantly improve progression-free survival (PFS) in people who have been previously untreated for advanced renal cell carcinoma (RCC).